Showing 1-10 of 11 "Nutritional and Metabolic Conditions "

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with linagliptin in patients ... Read more >

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

Study D5553C0003 is a 28-week, randomized, double-blind, active-controlled, multicenter, Phase 3 efficacy and safety study with a 24-week extension phase of simultaneous administration of exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg ... Read more >

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placeb ... Read more >

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placeb ... Read more >

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with T2DM and to compare outcomes against placebo, on a backg ... Read more >

Status: Enrolling

Investigator: Imran Mohiuddin

Study Coordinator: Sheila Moore

Phone: 713.441.3250

The objectives of this study are to collect post-market confirmatory evidence of the safety and effectiveness of the Bard® LifeStent® Vascular Stent System and LifeStent® XL Vascular Stent System (together the "LifeStent® Vascular Stent System") ... Read more >

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and at elevated risk ... Read more >

Status: Enrolling

Investigator: Dipan Shah

Study Coordinator: Bevin Lopez

Phone: 713.441.6537

The American Diabetes Association estimates that 25.8 million individuals or 8.3% of the United States population have diabetes mellitus (DM). Individuals with diabetes have an increased risk for cardiovascular disease (CVD) and CVD events accou ... Read more >

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events). Examples of major cardiovasc ... Read more >

Status: Open Not Enrolling

Investigator: Alan Lumsden

Study Coordinator: Kim Donlon

Phone: 713.441.9394

The purpose of this trial is to determine if the Ventana Fenestrated Stent Graft System is safe and effective for the endovascular repair of juxtarenal or pararenal aortic aneurysms. ... Read more >

Status: Enrolling

Investigator: Alan Lumsden

Study Coordinator: Kim Donlon

Phone: 713.441.9394

The purpose of the Zenith® p-Branch® OTS Multicenter Study is to provide an early clinical experience and evaluate the safety and effectiveness of the Zenith® p-Branch® in the treatment of pararenal or juxtarenal abdominal aortic aneurysms (AAA) ... Read more >